KR20240026998A - 클로스트리듐ㆍ디피실균의 증식을 억제하기 위한 모노클로날 항체 함유 조성물 - Google Patents
클로스트리듐ㆍ디피실균의 증식을 억제하기 위한 모노클로날 항체 함유 조성물 Download PDFInfo
- Publication number
- KR20240026998A KR20240026998A KR1020247001365A KR20247001365A KR20240026998A KR 20240026998 A KR20240026998 A KR 20240026998A KR 1020247001365 A KR1020247001365 A KR 1020247001365A KR 20247001365 A KR20247001365 A KR 20247001365A KR 20240026998 A KR20240026998 A KR 20240026998A
- Authority
- KR
- South Korea
- Prior art keywords
- amino acid
- ser
- acid sequence
- thr
- leu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Gram-positive bacteria
- C07K16/1282—Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JPJP-P-2021-110423 | 2021-07-02 | ||
| JP2021110423 | 2021-07-02 | ||
| PCT/JP2022/026399 WO2023277166A1 (ja) | 2021-07-02 | 2022-06-30 | クロストリジウム・ディフィシル菌の増殖を抑制するためのモノクローナル抗体含有組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240026998A true KR20240026998A (ko) | 2024-02-29 |
Family
ID=84692754
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247001365A Pending KR20240026998A (ko) | 2021-07-02 | 2022-06-30 | 클로스트리듐ㆍ디피실균의 증식을 억제하기 위한 모노클로날 항체 함유 조성물 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240417450A1 (https=) |
| EP (1) | EP4364755A4 (https=) |
| JP (2) | JP7430946B2 (https=) |
| KR (1) | KR20240026998A (https=) |
| CN (1) | CN117580590A (https=) |
| CA (1) | CA3224499A1 (https=) |
| WO (1) | WO2023277166A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240082370A (ko) * | 2021-09-30 | 2024-06-10 | 이구아루판 가부시키가이샤 | 모노클로널 항체 함유 조성물 |
| TW202440928A (zh) | 2023-03-03 | 2024-10-16 | 國立大學法人東京大學 | 免疫球蛋白 |
| CN121127591A (zh) * | 2023-05-12 | 2025-12-12 | 国立大学法人东京大学 | 与艰难梭菌结合的抗体 |
| WO2025220732A1 (ja) * | 2024-04-17 | 2025-10-23 | 国立研究開発法人国立循環器病研究センター | 肺高血圧症の予防又は治療薬 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090087478A1 (en) * | 2004-12-27 | 2009-04-02 | Progenics Pharmaceuticals (Nevada), Inc. | Orally Deliverable and Anti-Toxin Antibodies and Methods for Making and Using Them |
| US20110020356A1 (en) * | 2007-12-07 | 2011-01-27 | Lin Fang | Therapeutic clostridium difficile antibody compositions |
| PT2411410E (pt) * | 2009-03-27 | 2015-10-09 | Gojo Ind Inc | Composições e métodos para screening e utilização de compostos que antagonizam interações esporo-superfície |
| AR086199A1 (es) * | 2011-04-22 | 2013-11-27 | Wyeth Llc | Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos |
| US9815889B2 (en) * | 2011-08-02 | 2017-11-14 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | Antibodies for prevention and treatment of diseases caused by clostridium difficile |
| JP5916946B2 (ja) | 2013-03-11 | 2016-05-11 | 学校法人関西文理総合学園 | モノクローナルＩｇＡ抗体の製造方法 |
| JP2017001987A (ja) * | 2015-06-11 | 2017-01-05 | 学校法人関西文理総合学園 | ポリペプチド |
-
2022
- 2022-06-30 US US18/574,919 patent/US20240417450A1/en active Pending
- 2022-06-30 EP EP22833312.6A patent/EP4364755A4/en active Pending
- 2022-06-30 JP JP2022566304A patent/JP7430946B2/ja active Active
- 2022-06-30 CN CN202280046164.0A patent/CN117580590A/zh active Pending
- 2022-06-30 WO PCT/JP2022/026399 patent/WO2023277166A1/ja not_active Ceased
- 2022-06-30 KR KR1020247001365A patent/KR20240026998A/ko active Pending
- 2022-06-30 CA CA3224499A patent/CA3224499A1/en active Pending
-
2024
- 2024-01-25 JP JP2024009621A patent/JP2024046661A/ja active Pending
Non-Patent Citations (7)
| Title |
|---|
| Bry L, et al., Science 1996; 273：1380 |
| Cerf-Bensussan N, and Gaboriau-Routhiau V., Nat Rev Immunol 2010; 10：735 |
| Hooper LV, and Macpherson AJ., Nat Rev Immunol 2010; 10：159 |
| Round JL, and Mazmanian SK, Proc Natl Acad Sci USA 2010; 107：12204 |
| Shulzhenko N, et al., Nat Med 2011; 17：1585 |
| Turnbaugh PJ, et al., Nature 2006; 444：1027 |
| Vijay-Kumar M, et al., Science 2010; 328：228 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4364755A1 (en) | 2024-05-08 |
| CA3224499A1 (en) | 2023-01-05 |
| JPWO2023277166A1 (https=) | 2023-01-05 |
| JP2024046661A (ja) | 2024-04-03 |
| US20240417450A1 (en) | 2024-12-19 |
| CN117580590A (zh) | 2024-02-20 |
| WO2023277166A1 (ja) | 2023-01-05 |
| JP7430946B2 (ja) | 2024-02-14 |
| EP4364755A4 (en) | 2026-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20240026999A (ko) | 클로스트리듐ㆍ디피실균에 결합하는 항체 | |
| KR20240026998A (ko) | 클로스트리듐ㆍ디피실균의 증식을 억제하기 위한 모노클로날 항체 함유 조성물 | |
| CN109790218B (zh) | 抗tim-3抗体及其用途 | |
| US9765151B2 (en) | Method for producing monoclonal IgA antibody | |
| KR101683033B1 (ko) | 톨-유사 수용체 3 길항제 | |
| KR20220110539A (ko) | 치료 및 진단용 신규 분자 | |
| KR101758713B1 (ko) | 톨-유사 수용체 3 길항제 | |
| CN114366818A (zh) | 抗体药物偶联物及其应用 | |
| KR20140075708A (ko) | 대사 및 심혈관 질환의 치료를 위한 톨-유사 수용체 3 길항제 | |
| CN114040924B (zh) | 对lif具有特异性的结合分子及其用途 | |
| US20250051426A1 (en) | Composition containing monoclonal antibody | |
| RU2829997C1 (ru) | Антитело к cldn-18.2 и его применение | |
| WO2024237217A1 (ja) | クロストリジオイデス・ディフィシル菌に結合する抗体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20240112 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20250422 Comment text: Request for Examination of Application |